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Abstract
Background: Bronchoscopy is frequently used to sample the lower airways in lung microbiome studies. Despite
being a safe procedure, it is associated with discomfort that may result in reservations regarding participation in
research bronchoscopy studies. Information on participation in research bronchoscopy studies is limited. We report
response rates, reasons for non-response, motivation for participation, and predictors of participation in a large-scale
single-centre bronchoscopy study (“MicroCOPD”).
Methods: Two hundred forty-nine participants underwent at least one bronchoscopy in addition to being examined
by a physician, having lung function tested, and being offered a CT scan of the heart and lungs (subjects > 40 years).
Each participant was asked an open question regarding motivation. Non-response reasons were gathered, and
response rates were calculated.
Results: The study had a response rate just above 50%, and men had a significantly higher response rate than
women (56.5% vs. 44.8%, p = 0.01). Procedural fear was the most common non-response reason. Most
participants participated due to perceived personal benefit, but a large proportion did also participate to help
others and contribute to science. Men were less likely to give exclusive altruistic motives, whereas subjects
with asthma were more likely to report exclusive personal benefit as main motive.
Conclusion: Response rates of about 50% in bronchoscopy studies make large bronchoscopy studies feasible,
but the fact that participants are motivated by their own health status places a large responsibility on the
investigators regarding the accuracy of the provided study information.
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Introduction
Although primarily employed as a diagnostic tool, bron-
choscopy is useful in studies on airway inflammation,
bronchial remodelling, and the airway microbiota.
Studies on airway microbiota have so far been relatively
low-powered [1–3], and future studies will depend on
larger samples. Even if bronchoscopy is associated with a
low complication rate [4], some discomfort is inevitable,
and potential participants may therefore have reserva-
tions [5]. Knowledge on motives for participation and re-
sponse rates in bronchoscopy studies have the potential
to optimise the recruitment process.
However, there are few studies providing reliable re-
sponse rates and motives for participation in bronchoscopy
studies. A literature review on research bronchoscopy stud-
ies included seven relevant studies, and found personal
benefit and altruistic reasons to be the most important par-
ticipation motives, whereas fear of the bronchoscopy was
reported as a participation barrier [6]. Response rates from
the seven studies varied from 3 to 73%, and no study exam-
ined participation among subjects with chronic obstructive
pulmonary disease (COPD) in particular [6].
The Bergen COPD Microbiome study (“MicroCOPD”)
is a large single-centre study of the airway microbiota,
with bronchoscopic sampling of all participants. Data
was collected at the Department of Thoracic Medicine,
Haukeland University Hospital in Bergen, Norway, be-
tween April 2013 and June 2015. The main objective in
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the MicroCOPD study was to examine and compare air-
way microbiota from subjects without COPD (controls)
and subjects with COPD. Some subjects with asthma
were also included. The current paper reports re-
sponse rates, reasons for non-response, motivation for
participation, and predictors of participation in the
MicroCOPD study.
Methods
Study design and population
The MicroCOPD study was a single-centre prospective,
observational study carried out in Bergen, Western
Norway. The study design has been described previously
[7]. A pilot study of eight subjects with COPD was con-
ducted in 2012 for protocol improvement. Participants
from the pilot and main study were included in the
current analyses. The main study included its first par-
ticipant on April 11th, 2013, with the final study bron-
choscopy performed June 5th, 2015. The study was
conducted in accordance with the declaration of
Helsinki and guidelines for good clinical practice. The
regional committee of medical ethics approved the pro-
ject (project number 2011/1307), and all participants
provided informed written consent.
Controls and subjects with COPD or asthma were
mainly recruited among participants of two previous stud-
ies performed by our research groups; the GeneCOPD
study from 2003 to 2004 [8] and the Bergen COPD cohort
study from 2006 to 2009 [9–12]. In addition, 6 subjects
were recruited from outpatient clinics, and 8 subjects were
recruited by their own initiative through attention from
local media and hospital staff.
All subjects from the two previous studies who still
lived in Bergen or the closest surrounding municipalities
were eligible for participation. Potential participants
were screened by an interview performed by a study
physician regarding exclusion criteria for bronchoscopy
before giving informed consent. We did not include sub-
jects with increased bleeding risk, subjects with unstable
cardiac conditions, or subjects with hypercapnia or hyp-
oxaemia when receiving oxygen supplement [7]. Elderly
subjects judged frail by the study physician were ex-
cluded. Participation was postponed for subjects that
had used antibiotics or oral corticosteroids in the last 14
days, as well as subjects with symptoms of acute exacer-
bation of COPD.
Data collection
Subjects that declined participation at the screening
interview were asked about their non-response reason.
Participants attended the outpatient clinic over one or
two days depending on the availability of computed tom-
ography (CT) scanning. A pulmonary and coronary CT
scan was offered as part of a concurrent study, and this
would be performed prior to bronchoscopy if the partici-
pants were scheduled for both procedures. At the day of
bronchoscopy, prior to the procedure, participants
underwent a structured interview regarding their medical
history, respiratory symptoms, smoking habits, medication
use, motivation, and exacerbation frequency if they had
obstructive lung disease. An open question on motivation
was first included in the study questionnaire from the fifth
pilot patient, asked immediately prior to the procedure.
Additionally, post-bronchodilator spirometry was per-
formed and blood samples were collected.
Diagnoses of COPD and asthma were evaluated by the
study physician, based on medical history, symptoms,
pulmonary CT scan, and post-bronchodilator spirometry
[13, 14]. Controls were judged to have no sign of airway
or lung disease, based on the same information. After all
participants were included, a panel of three physicians
evaluated the diagnoses for a quality control regarding
possible misclassification between controls and subjects
with COPD or asthma.
The bronchoscopy procedure was explained in detail
to each participant by the study physician immediately
prior to the procedure. The procedure was performed
with the participant in the supine position, with the
option of light sedation (alfentanil, potentially com-
bined with midazolam). Samples were gathered by
sterile brushes and bronchoalveolar lavage (BAL) after
application of a local anaesthetic agent. Additionally,
gathering of bronchial biopsies began in May 2014.
The details of bronchoscopic sampling have been pre-
viously published [7]. The average length of the bron-
choscopy procedures was 15 min, including
bronchoscopies with bronchial biopsies.
Outcomes
Responders were subjects who accepted the invitation
and underwent a bronchoscopy. Non-responders were
subjects who did not undergo a bronchoscopy. Late
non-responders were subjects who reconsidered an ini-
tial decision to participate, or when bronchoscopies were
terminated before sampling due to participant discom-
fort. All non-responders were asked about their reason
to decline participation. The response rate was defined
as the number of bronchoscopies performed divided by
the number of invited subjects.
Participation motives were collected from an open
question before bronchoscopy started: “Why did you
wish to take part in this project?”. Participants could
provide more than one motive for participation, thus the
overall numbers of motives exceeded the numbers of
participants. At the time of analysis we initially merged
the unique motives into 16 more principal motives, and
then further classified these into three main groups: 1)
Altruism was motivation by a wish to help others or a
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wish to continue participation from previous studies, as
well as desire to contribute to science. 2) Personal benefit
was motivation by a wish to somehow improve own health
by participating in the project. 3) Obligation was a subject-
ive feeling of being bound to participate. Subjects without
specific reasons were labelled missing. We constructed
binary variables “exclusive altruism” and “exclusive per-
sonal benefit” by coding them as ‘1’ if the participant only
gave altruism or personal benefit as main motive, respect-
ively. Participants stating both altruism and personal
benefit, or altruism/personal benefit and obligation, were
coded ‘0’ on these variables.
Statistical analyses
All analyses were performed using Stata version 14 [15].
Response rates were stratified by sex and study category
(control/obstructive lung disease). Chi-square test or
Fisher’s exact test was used to compare frequencies of
non-response reasons.
Bivariate analyses of responders and non-responders,
as well as initial and late non-responders, were per-
formed using parametric (t-test) and non-parametric
tests (chi-square test or Fisher’s exact test), when judged
appropriate. Bivariate logistic regression models were
fitted with “exclusive altruism” or “exclusive personal
benefit” as outcome. Covariates with p less than 0.20 be-
fore adjustment were included in multivariate models. In
the logistic regression, age and FEV1 were treated as
continuous variables, but divided by 10 to provide ratios
for an increase of 10 units. Smoking habits were grouped
according to current smoking status (never-, ex-,
current-smokers), and we calculated number of pack/
years (cigarettes per day divided by 20, multiplied by
years smoking). Never-smokers and ex-smokers were
merged into one category in the logistic regression ana-
lysis. Lung function was analysed using the percentage
of predicted values of FEV1 and FVC, as well as the
FEV1/FVC-ratio. Dyspnoea was classified according to
the modified Medical Research Council (mMRC) dys-
pnoea scale [16].
Results
Flow chart (Fig. 1)
In total, 2,205 subjects from the two previous COPD co-
horts were considered potential participants for the
MicroCOPD study. 1,743 were ineligible, mainly due to
death or that the MicroCOPD inclusion period ended
(see Additional file 1: Table S1 for details). The total
number of invited individuals for bronchoscopy was 462,
of whom 323 subjects accepted the invitation. 85 sub-
jects reconsidered their decision to participate, and fur-
ther three bronchoscopies were terminated before
sampling due to participant discomfort.
Response rates
Since the denominator of the response rate for subjects
recruited from outpatient clinics, local media, and hos-
pital staff was unknown, these 14 subjects were excluded
from the response-rate analyses. Final response rate for
the main study was 50.9%. The response rates in women
and men were 44.8% (100/223) and 56.5% (135/239), re-
spectively (p = 0.01). No significant difference in attend-
ance was seen between subjects without obstructive lung
disease and subjects with COPD or asthma.
Demographics of responders and non-responders (Table 1)
There was no significant difference in age between re-
sponders and non-responders or between early or late re-
sponders. Whereas responders and initial non-responders
did not differ by study category, there was a larger number
of patients among the late non-responders compared with
initial non-responders.
Non-response reasons (Table 2)
Most initial non-responders stated that they feared the
discomfort of a bronchoscopy (23.7%), and together with
unspecific fear and worries related to study participation
this accounted for 40.2% of all the initial non-response.
The percentage of worries and fears in late non-re-
sponders was more than twice as high (p < 0.01). Among
the initial non-responders there was a higher expression
of study fatigue (10.1% vs. 2.3%, p = 0.03). A considerable
number of the non-responders felt that their own health
prevented participation (17.3% in initial non-responders,
and 26.1% in late non-responders), and most so in
subjects with obstructive lung diseases (p < 0.01).
Detailed demographics of responders (Table 3)
The majority of responders were ex-smokers (68.3%),
and a minority were never-smokers (9.6%). Age and sex
were not significantly different between the controls and
subjects with COPD. However, there were more
ex-smokers and higher number of pack/years, less edu-
cation, fewer married, more drug use, more comorbidi-
ties, as well as higher symptom burden and lower lung
function among the subjects with COPD (p ≤ 0.01, tests
not shown).
Motivation (Table 4)
Personal health benefit was the most common stated
principal motive for participation (49.0%), followed by
contribution to science (39.2%). 39 subjects (15.9%) also
mentioned helping others as motivation. After merging
into broader categories, primarily altruism was the main
motive stated by most participants (67.3%), while 52.2%
gave motives considered to be of personal benefit. Only
2.0% participated out of a sense of obligation.
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Frequencies on motives were also stratified by
participant group, i.e. control, COPD, and asthma (see
Additional file 1: Table S2 for details).
Men were less likely to state altruism as their main
motive for participation (Fig. 2a, odds ratio (OR) 0.6,
95% confidence interval (0.3, 0.9)). This effect was more
pronounced in the adjusted model, OR = 0.5 (0.3, 0.9).
More subjects with asthma stated personal benefit mo-
tives than controls, unadjusted OR = 4.4 (1.5, 13.3), ad-
justed OR = 5.1 (1.6, 16.0) (Fig. 2b). No significant effect
was observed by FEV1 in percentage of predicted, age,
number of comorbidities, education, or smoking status.
Discussion
We have reported response rates, non-response reasons,
and motives for participation in a large single-centre
bronchoscopy study. Response rates were about 50%,
and did not differ between controls and subjects with
COPD or asthma. The main reasons for non-response
were fear of discomfort from the bronchoscopic proced-
ure, and a subjective feeling of being diseased or too
bothered from health issues to participate, especially
among subjects with COPD or asthma. Participants were
most frequently motivated by altruistic motives, but less
so for men.
Table 1 Demographics of responders and non-responders in an observational research bronchoscopy study
Variable Responders
n = 235
Non-responders p-* p**
Initial, n = 139 Late, n = 88
Age (SD) 66.9 (7.6) 67.9 (8.0) 67.4 (7.5) 0.3 0.6
Sex 0.01 0.5
Women (%) 42.6 56.1 51.1
Men (%) 57.4 43.9 48.9
Study category 0.2 0.06
Controls (%) 43.0 41.7 29.6
Obstructive lung disease (%) 57.0 58.3 70.4
*Difference between responders and all non-responders
**Difference between initial and late non-responders
Fig. 1 Flow chart of an observational research bronchoscopy study. * Local media, hospital staff, and outpatient clinics were regarded as
other sources
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Table 2 Self-reported non response-reasons in an observational research bronchoscopy study
Reasons Non-responders Study category
Initial, n = 139
Frequency (%)
Late,
n = 88
Frequency (%)
p Controls, n = 84
Frequency (%)
OLD, n = 143
Frequency (%)
p
Discomfort 33 (23.7) 16 (18.2) 0.3 19 (22.6) 30 (21.0) 0.2
Unspecified worries/fear concerning participation 23 (16.5) 30 (34.1) < 0.01 19 (22.6) 34 (23.8) 0.08
Disease/health issues 24 (17.3) 23 (26.1) 0.1 8 (9.5) 39 (27.3) < 0.01
Study fatigue 14 (10.1) 2 (2.3) 0.03 5 (6.0) 11 (7.7) 0.2
Time constraint 5 (3.6) 5 (5.7) 0.5 7 (8.3) 3 (2.1) 0.2
Practicala 5 (3.6) 6 (6.8) 0.3 5 (6.0) 6 (4.2) 0.9
Not satisfied with previous study participation 2 (1.4) 0 0.5 0 2 (1.4) 0.5
Feeling too old 2 (1.4) 0 0.5 2 (2.4) 0 0.2
Refuse to specify 1 (0.7) 0 1.0 1 (1.2) 0 0.5
Personal reason 0 3 (3.4) 0.06 1 (1.2) 2 (1.4) 1.0
Not specified 30 (21.6) 3 (3.4) < 0.01 17 (20.2) 16 (11.2) 0.7
OLD obstructive lung disease
aPractical reflects practical issues for researcher or patient
Table 3 Demographics of participants in an observational research bronchoscopy study
Variable All, n = 249 Control, n = 103 COPD, n = 130 Asthma, n = 16
Age (SD) 66.3 (8.3) 65.3 (8.6) 67.2 (7.3) 65.5 (12.6)
Sex (men) 143 (57.4) 60 (58.3) 76 (58.5) 7 (43.8)
Number of medications (SD) 3.8 (3.2) 1.8 (1.7) 5.4 (3.3) 3.6 (2.4)
Number of comorbidities (SD) 1.1 (1.1) 0.8 (1.0) 1.4 (1.2) 0.8 (0.9)
FEV1, % of predicted (SD) 78.3 (28.2) 103.9 (12.3) 56.5 (19.2) 90.7 (13.3)
FVC, % of predicted (SD) 102.7 (18.7) 111.7 (13.5) 95.0 (19.2) 107.5 (16.5)
FEV1/FVC-ratio (SD) 0.6 (0.2) 0.7 (0.1) 0.5 (0.1) 0.7 (0.1)
Pack/years (SD)a 28.6 (20.1) 21.6 (16.9) 33.7 (20.5) 20.9 (22.0)
Smoking status (%)
Daily 55 (22.1) 25 (24.3) 30 (23.1) 0 (0.0)
Ex-smokers 170 (68.3) 59 (57.3) 99 (76.2) 12 (75.0)
Never 24 (9.6) 19 (18.5) 1 (0.8) 4 (25.0)
Marital status (%)a
Married/partner 157 (64.3) 79 (77.5) 72 (57.1) 6 (37.5)
Widowed 22 (9.0) 3 (2.9) 16 (12.7) 3 (18.8)
Cohabitant 20 (8.2) 5 (4.9) 13 (10.3) 2 (12.5)
Divorced, lives alone 33 (13.5) 11 (10.8) 17 (13.5) 5 (31.3)
Single 12 (4.9) 4 (3.9) 8 (6.4) 0 (0.0)
Education (%)a
Primary school 48 (19.8) 12 (11.8) 35 (27.8) 1 (6.7)
Upper secondary/high school 125 (51.4) 52 (51.0) 67 (53.2) 6 (40.0)
3 years or more of higher education 70 (28.8) 38 (37.3) 24 (19.1) 8 (53.3)
mMRC Grade 2 and higher (%)
Grade 2 level ground 30 (54.6) 3 (100) 27 (52.9) 0 (0.0)
Grade 3100 m 18 (32.7) 0 (0.0) 17 (33.3) 1 (100)
Grade 4 resting dyspnoea 7 (12.7) 0 (0.0) 7 (13.7) 0 (0.0)
FEV1 Forced Expiratory Volume in 1 Second, FVC Forced Vital Capacity, and mMRC modified Medical Research Council dyspnoea scale
aDue to some missing information, the sum of participants is not 249
Martinsen et al. Multidisciplinary Respiratory Medicine           (2019) 14:14 Page 5 of 9
Given the invasiveness of the involved procedures, a
response rate of 50% is not remarkably low. Little data
exists on participation in research bronchoscopy studies
[6]. Neither of seven Norwegian respiratory health sur-
veys studies between 1965 and 1999 included a bron-
choscopy, but baseline response rates varied from 68 to
90% [17]. Once attending, only 5% of attendants did
not complete their participation [17]. In the current
study, 27.2% (88/323) reconsidered their decision,
suggesting higher rates of reconsideration with more
invasive procedures.
A trend towards lower participation rates has been ob-
served in Norwegian studies over time [17, 18]. This
trend could at worst lead to selection bias and compro-
mised external validity. In general, young, single men
living in urban areas are the least likely to participate in
social science surveys, while older women are the most
willing [18]. In the current study, more men than
women were responders. Experiences from clinical work
suggest that women worry more about clinical
procedures, and this could serve as a possible explan-
ation for the observed difference. Additionally, more
men were motivated by perceived personal benefit. If
this observation stands true, one could speculate that
male motivation is more easily satisfied by participation
in a clinical study involving an actual diagnostic proced-
ure, than participation in a questionnaire study. We ob-
served no difference in mean age between responders
and non-responders, but younger individuals were omit-
ted from the current study, and frail elders were ex-
cluded. In another Norwegian study on respiratory
health, non-response was related to lower age, rural
habitation, and smoking habits [19]. Response rates from
the current study will help researchers scale the number
of invited subjects, aiming to recruit a sufficient number
of participants, in order to avoid type II errors. These
numbers can also be of value when investigators seek
funding and ethics approval, providing precise informa-
tion regarding the inclusion process.
Knowledge of reasons for non-response could guide re-
searchers to provide precise information regarding the
procedure during recruitment, which in turn might
influence the willingness to participate. Observed differ-
ence in worries/fear between initial and late non-re-
sponders suggests that participants become frightened
during the waiting time. Information on relevant discom-
fort should always be disclosed at first contact to avoid
unreasonably procedural fear, and unnecessary waiting
time before scheduled procedures should be avoided, both
for research and clinical purposes. This will reduce costs
and planning of non-performed procedures.
In agreement with the literature, we could categorise
motives for participation into three groups, namely per-
sonal benefit, altruism, and obligation [6], although the re-
view stated obedience to the authority of the researchers as
an own group. Only one subject claimed trust in author-
ity/research to be of importance in the current study. This
discrepancy with previous studies might reflect both cul-
tural differences and differences in health care organisa-
tion. Furthermore, patients are increasingly making their
own health decisions [20], which might have changed the
view of physicians as authorities.
We observed that women expressed more altruistic
motives than men. In concordance with the current
study, a meta-analysis on altruism and gender by Rand
et al. showed women to be more intuitively altruistic,
and men to be more selfish both intuitively and after
consideration [21]. Our observation that subjects with
asthma tend to report personal benefit needs to be inter-
preted with some caution. There were few subjects with
asthma in our study, and they were recruited in a
non-controlled manner.
Our results indicate that providing information on fu-
ture implications of research can promote participation
Table 4 Motives reported by the 245a participants who gave
motives in an observational research bronchoscopy study
Motives n Percentage
Primarily altruismb 165 67.3
Previous participation 23 9.4
Contribute to science 96 39.2
Help others 39 15.9
Give back (for previous participation) 7 2.9
Generally positive (to examination or
participation and “yes-human”)
6 2.4
Social responsibility 3 1.2
COPD in family/among friends
(including risk of COPD in family)
19 7.8
Available time 3 1.2
Primarily personal benefitb 128 52.2
Personal health benefit 120 49.0
Experience the discomfort of
bronchoscopy
1 0.4
Challenge 1 0.4
Curiosity 14 5.7
Fun 1 0.4
Primarily obligationb 5 2.0
Acquaintance (in study, working with and
was connected to the study or asked by)
4 1.6
Trust in authority/research 1 0.4
Missing 20 8.2
aParticipation was not part of the questionnaire for the first four participants
bUnique motives are categorised into three main motives (in italic) by merging
the unique motives listed below the main motive. The frequency (n) of main
motives is not equal to the sum of each principal motive because a subject
stating both "personal health benefit" and "challenge" would result in two
observations in principal motives, but just one after merging
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by appealing to a desire to contribute to science and fu-
ture health care. Emphasising potential health benefits of
study participation would probably have an even greater
effect, but this warrants caution. Screening effects of
bronchoscopy are not known. Also, there is a small compli-
cation risk associated with the procedure [4]. Participants
were offered participation also in a concurrent study
wherein a CT scan was offered, however participation in ei-
ther study was not dependent on participation in the other.
Thus, no exclusive, immediate benefit was received for the
participants in the MicroCOPD study. Even though this
was clearly stated in the written consent, almost half of the
final participants stated personal benefit as an important
motive. Participants’ expectation of perceived health benefit
from participation is well known from the literature, even
though no such benefit should be expected [5, 22], also
where this is clearly stated by the research team [23]. Thus,
we believe that participants´ perceived personal benefit in
observational studies should be examined more thoroughly
in future studies.
The MicroCOPD study is, to our knowledge, the lar-
gest single-centre lung microbiome study performed to
date. We had extensive demographics on responders,
and reliable results on motivation and non-response rea-
sons. Some potential weaknesses deserve mentioning.
Firstly, due to ethical and practical reasons, demograph-
ics on non-responders were sparse, and a considerable
proportion of non-responders did not give any reason
for their decline. Secondly, albeit a large study, the
heterogeneity of the participants may have obscured
the finding of important predictors of participation
and motivation. Thirdly, an in-depth interview could
have provided more insight into the details of
non-response and motivation. Finally, most partici-
pants had already shown a willingness to take part in
previous studies. Hence, they might be more prone to
take part than a general population, generating some
degree of selection bias. On the other hand, “study fa-
tigue” might have lowered the participation rate in
the current study.
a
b
Fig. 2 Logistic regression on a) exclusive altruism- and b) exclusive personal benefit-variables in an observational research bronchoscopy study
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Conclusions
The response rate for research bronchoscopy in our
study was 50%, and did not differ between controls and
subjects with COPD or asthma. Non-responders refused
participation mainly due to procedural fear. In contrast,
responders were driven by perceived personal benefit,
but a large proportion did also participate to help others
and contribute to science. Our findings underline the
importance of providing comprehensive information
about the procedures. This might serve to avoid refusal
on a possible misunderstood risk assessment, and to se-
cure inclusion of a sufficient number of well-informed
participants.
Additional file
Additional file 1: Table S1. Reasons for ineligibility in an
observational research bronchoscopy study, n = 1743. Table S2.
Motives reported by the 245a participants who gave motives in an
observational research bronchoscopy study stratified by participant
group. (PDF 96 kb)
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